National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings, 61694 [E9-28289]
Download as PDF
<![CDATA[
61694
Federal Register / Vol. 74, No. 226 / Wednesday, November 25, 2009 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Meeting
sroberts on DSKD5P82C1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of an Interagency Autism
Coordinating Committee (IACC)
meeting.
The purpose of the IACC meeting is
to continue discussing
recommendations for the annual update
of the IACC Strategic Plan for Autism
Spectrum Disorders Research. The IACC
meeting will be conducted and available
to the public via a telephone conference
call and a webinar.
Name of Committee: Interagency Autism
Coordinating Committee (IACC)
Type of meeting: Open meeting via
conference call and webinar only; no inperson meeting.
Date: December 11, 2009.
Time: 9 a.m. to 1 p.m.* Eastern Time—*
Approximate end time.
Meeting Registration: No registration is
required to listen to the conference call or
view the webinar.
Agenda: To continue discussion on
recommendations for the annual update of
the IACC Strategic Plan for Autism Spectrum
Disorder Research.
Webinar: https://www2.gotomeeting.com/
register/906979171.
Conference Call Access: Dial: 888–455–
2920. Access code: 9984461.
Contact Person: Ms. Lina Perez, Office of
Autism Research Coordination, Office of the
Director, National Institute of Mental Health,
NIH, 6001 Executive Boulevard, NSC, Room
8200, Bethesda, MD 20892–9669, Phone:
(301) 443–6040, E-mail:
IACCPublicInquiries@mail.nih.gov.
Any interested person may submit written
comments to the IACC prior to the meeting
by sending the statement to the Contact
Person listed on this notice by 5 p.m. ET on
December 8, 2009. The statement should
include the name, address, telephone number
and when applicable, the business or
professional affiliation of the interested
person. All written statements received by
the deadline will be provided to the IACC for
their consideration.
The meeting will be open to the public
through a conference call phone number and
a webinar conducted using a web
presentation tool on the Internet. Individuals
who participate using this service and who
need special assistance, such as captioning of
the conference call or other reasonable
accommodations, should submit a request to
the contact person listed above at least seven
days prior to the meeting. If you experience
any technical problems with the Web
presentation tool or conference call, please
e-mail
IACCTechSupport@acclaroresearch.com.
Members of the public who participate
using the conference call phone number will
VerDate Nov<24>2008
17:36 Nov 24, 2009
Jkt 220001
be able to listen to the meeting but will not
be heard. This phone call may end prior to
or later than 1 p.m., depending on the needs
of the Committee.
To access the webinar on the Internet the
following computer capabilities are required:
(A) Internet Explorer 5.0 or later, Netscape
Navigator 6.0 or later or Mozilla Firefox 1.0
or later; (B) Windows® 2000, XP Home, XP
Pro, 2003 Server or Vista; (C) Stable 56k,
cable modem, ISDN, DSL or better Internet
connection; (D) Minimum of Pentium 400
with 256 MB of RAM (Recommended); (E)
Java Virtual Machine enabled
(Recommended)
This meeting is being published less than
15 days prior to the meeting due to the
timing limitations for completing the
updating of the Annual Strategic Plan for
Autism Spectrum Disorder Research.
Information about the IACC is available on
the Web site: https://www.iacc.hhs.gov.
Meeting schedule subject to change.
Dated: November 19, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–28284 Filed 11–24–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; Clinical
Trial Grant Review.
Date: December 8, 2009.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Eric H. Brown, PhD,
Scientific Review Officer, National Institute
of Arthritis, Musculoskeletal and Skin
Diseases, National Institutes of Health, 6701
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Democracy Blvd., Room 824, Msc 4872,
Bethesda, MD 20892–4872, (301) 594–
4955,browneri@mail.nih.gov.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; Providing
Radiologic Outcomes for the Osteoarthritis
Initiative.
Date: December 16, 2009.
Time: 10 a.m. to 11:30 a.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Charles N. Rafferty, PhD,
Chief, Review Branch, National Institute of
Arthritis, Musculoskeletal and Skin Diseases,
National Institutes of Health, 6701
Democracy Boulevard, Suite 800, Bethesda,
MD 20817, 301–534–4952,
raffertycn@mail.nih.gov.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; Clinical
Outcome Instrument Development.
Date: January 26, 2010.
Time: 8 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Michael L. Bloom, PhD.,
MBA, Scientific Review Officer, National
Institute of Arthritis, Musculoskeletal and
Skin Diseases, National Institutes of Health,
6701 Democracy Blvd.; Room 820, MSC
4872, Bethesda, MD 20892–4872, 301–594–
4953, Michael_Bloom@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: November 19, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–28289 Filed 11–24–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
E:\FR\FM\25NON1.SGM
25NON1
]]>Agencies
[Federal Register Volume 74, Number 226 (Wednesday, November 25, 2009)]
[Notices]
[Page 61694]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-28289]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Arthritis and
Musculoskeletal and Skin Diseases Special Emphasis Panel; Clinical
Trial Grant Review.
Date: December 8, 2009.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Eric H. Brown, PhD, Scientific Review Officer,
National Institute of Arthritis, Musculoskeletal and Skin Diseases,
National Institutes of Health, 6701 Democracy Blvd., Room 824, Msc
4872, Bethesda, MD 20892-4872, (301) 594-4955,browneri@mail.nih.gov.
Name of Committee: National Institute of Arthritis and
Musculoskeletal and Skin Diseases Special Emphasis Panel; Providing
Radiologic Outcomes for the Osteoarthritis Initiative.
Date: December 16, 2009.
Time: 10 a.m. to 11:30 a.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, One Democracy Plaza, 6701
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Charles N. Rafferty, PhD, Chief, Review Branch,
National Institute of Arthritis, Musculoskeletal and Skin Diseases,
National Institutes of Health, 6701 Democracy Boulevard, Suite 800,
Bethesda, MD 20817, 301-534-4952, raffertycn@mail.nih.gov.
Name of Committee: National Institute of Arthritis and
Musculoskeletal and Skin Diseases Special Emphasis Panel; Clinical
Outcome Instrument Development.
Date: January 26, 2010.
Time: 8 a.m. to 1 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road, NW., Washington, DC 20015.
Contact Person: Michael L. Bloom, PhD., MBA, Scientific Review
Officer, National Institute of Arthritis, Musculoskeletal and Skin
Diseases, National Institutes of Health, 6701 Democracy Blvd.; Room
820, MSC 4872, Bethesda, MD 20892-4872, 301-594-4953, Michael_Bloom@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research; 93.701, ARRA
Related Biomedical Research and Research Support Awards, National
Institutes of Health, HHS)
Dated: November 19, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-28289 Filed 11-24-09; 8:45 am]
BILLING CODE 4140-01-P
